All In Biotech

NDA 020712 · Takeda Pharms USA

Carbatrol

Carbamazepine · Oral · Mood Stabilizer

Last checked: Nov 20, 2026Latest source record: Apr 11, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1997

Sep 30, 1997

Approved uses

1

Original approval plus efficacy supplements

Registered trials

199

31 Phase 3, 6 recruiting

FAERS reports

37,978

33,344 serious, 3,926 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING SERIOUS DERMATOLOGIC REACTIONS AND HLA-B*1502 ALLELE SERIOUS AND SOMETIMES FATAL DERMATOLOGIC REACTIONS, INCLUDING TOXIC EPIDERMAL NECROLYSIS (TEN) AND STEVENS-JOHNSON SYNDROME (SJS), HAVE BEEN REPORTED DURING TREATMENT WITH CARBAMAZEPINE. THESE REACTIONS ARE ESTIMATED TO OCCUR IN 1 TO 6 PER 10,000 NEW USERS IN COUNTRIES WITH MAINLY CAUCASIAN POPULATIONS, BUT THE RISK IN SOME ASIAN COUNTRIES IS ESTIMATED TO BE ABOUT 10 TIMES HIGHER. STUDIES IN PATIENTS OF CHINESE ANCESTRY HAVE FOUND A STRONG ASSOCIATION BETWEEN THE RISK OF DEVELOPING SJS/TEN AND THE PRESENCE OF HLA-B*1502, AN INHERITED ALLELIC VARIANT OF THE HLA-B GENE. HLA-B*1502 IS FOUND ALMOST EXCLUSIVELY IN PATIENTS WITH ANCESTRY ACROSS BROAD AREAS OF ASIA. PATIENTS WITH ANCESTRY IN GENETICALLY AT-RISK POPULATIONS SHOULD BE SCREENED FOR THE PRESENCE OF HLA-B*1502 PRIOR TO INITIATING TREATMENT WITH CARBATROL ® . PATIENTS...

What it is approved for

From the label in effect Aug 17, 2026.

INDICATIONS AND USAGE Epilepsy Carbatrol is indicated for use as an anticonvulsant drug. Evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvements than those with other types. Generalized tonic-clonic seizures (grand mal). Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petit mal) do not appear to be controlled by carbamazepine (see PRECAUTIONS, General ). Trigeminal Neuralgia Carbatrol is indicated in the treatment of the pain associated with true trigeminal neuralgia. Beneficial results have also been reported in glossopharyngeal neuralgia. This drug is not a simple analgesic and should not be used for the relief of trivial aches or pains.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 30, 1997 Original approval · Type 3 - New Dosage Form Review
3 products under this application
  • CARBATROL · CARBAMAZEPINE 100MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • CARBATROL · CARBAMAZEPINE 200MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • CARBATROL · CARBAMAZEPINE 300MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Carbamazepine" as an intervention, any sponsor and status, largest first.

All 199 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective3,626
  • drug interaction2,517
  • toxicity to various agents2,368
  • seizure2,098
  • off label use1,937
  • fall1,923
  • dizziness1,591
  • fatigue1,481
  • pain1,441
  • pyrexia1,418
  • condition aggravated1,303
  • somnolence1,291

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004673
2005827
2006818
2007726
2008951
20091,109
20101,018
20111,261
20121,443
20131,170
20141,318
20151,743
20161,935
20172,045
20182,816
20192,638
20202,213
20212,638
20222,423
20232,133
20242,105
20252,228
20261,741

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Dec 19, 2025

    Carbatrol, Capsule, Extended Release, 200 mg (NDC 54092-172-12). Discontinuation of the manufacture of the drug

  • To Be Discontinued · updated Dec 19, 2025

    Carbatrol, Capsule, Extended Release, 300 mg (NDC 54092-173-12). Discontinuation of the manufacture of the drug

  • To Be Discontinued · updated Dec 19, 2025

    Carbatrol, Capsule, Extended Release, 100 mg (NDC 54092-171-12). Discontinuation of the manufacture of the drug

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Carbatrol (Carbamazepine)

2024 spending

$3.2M

Beneficiaries

1,749

11,532 claims

Per beneficiary

$1,856

$1.75 per unit

View as table
YearSpending
2020$4,296,339
2021$4,012,710
2022$3,825,884
2023$3,558,086
2024$3,246,654

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,597 on PubMed

Sponsor: Takeda

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.